Sonnet BioTherapeutics Holdings Total Liabilities

Sonnet BioTherapeutics Holdings posts a total liabilities of $4.1M as of September 2025. That compares with $3.3M in the prior-year period — up 25.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sonnet BioTherapeutics Holdings's total liabilities was $3.3M. The latest reading is $4.1M — a 25.8% year-over-year increase (period ending September 2025). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Sonnet BioTherapeutics Holdings's financial statement story. At $4.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SONN's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sonnet BioTherapeutics Holdings's other metric pages and overview cover the third.

Judging Sonnet BioTherapeutics Holdings against Consumer Staples peers is usually better than using a market-wide rule of thumb. Business models inside Consumer Staples are more comparable, which makes gaps in total liabilities easier to interpret. Start with $4.1M here, then scan peer and history charts to see if the gap is persistent.